Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amoxicillin/clavulanic acid - Longbio Pharma

Next Previous
Drug Profile

Amoxicillin/clavulanic acid - Longbio Pharma

Alternative Names: LP 001; LP-001 - Longbio Pharma

Latest Information Update: 18 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LongBio Pharma
  • Developer Kaizen Bioscience; LongBio Pharma
  • Class 2 ring heterocyclic compounds; Antibacterials; Antibodies; Azetidines; Beta-lactams; Carboxylic acids; Oxazolidinones; Penicillins; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Otitis media
  • Phase I Bacterial infections; Myelodysplastic syndromes; Renal failure

Most Recent Events

  • 16 Dec 2024 Kaizen Bioscience completes phase-I clinical trials in Bacterial infections (In infants) in USA (PO) (NCT05584683)
  • 14 Nov 2024 Phase-III clinical trials in Otitis media (In children, In infants) in USA (unspecified route), prior to November 2024 (Kaizen Bioscience pipeline, November 2024)
  • 14 Nov 2024 Kaizen Bioscience plans to submit NDA for Otitis media in the first half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top